RE:ThoughtsYou have to admit that the allegation that the CanvasRx acquisition was made in large part to achieve performance milestones that would unlock 20m shares at zero cost to management sets up conflicting incentives. $43M for a small database of medical patients does make you wonder if there were ulterior motives - other than creating 'shareholder value'. no?